Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Tanaffos|April 5, 2021
Clinical Significance of Quantitative FDG PET/CT Parameters in Non-Small Cell Lung Cancer PatientsMohammad Behgam Shadmehr, Adnan Khosravi, Azizollah Abbasi Dezfouli, et al.
Iranian Biomedical Journal|September 18, 2024
Assessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for EGFR Mutation Detection in NSCLMohammad Mehdi Jahani, Parisa Mashayekhi, Mir Davood Omrani, et al.
Clinical and Translational Medicine|April 20, 2019
Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancerHanifeh Mirtavoos-Mahyari, Soudeh Ghafouri-Fard, Adnan Khosravi, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|May 28, 2022
Expression of miRNA1, miRNA133, miRNA191, and miRNA24, as Good Biomarkers, in Non-Small Cell Lung Cancer Using Real-Time PCR MethodMehdi Kazempour Dizaji, Behrooz Farzanegan, Naghmeh Bahrami, et al.
Journal of Inflammation (London, England)|August 12, 2014
Elevated CXCL-8 expression in bronchoalveolar lavage correlates with disease severity in patients with acute respiratory distress syndrome resulting from tuberculosisSeyed Mohamad Reza Hashemian, Esmaeil Mortaz, Payam Tabarsi, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|August 28, 2019
Three Markers in Cancerous and Healthy Cells of Patients with Non-Small-Cell Lung Carcinoma (NSCLC)Hamidreza Jamaati, Adnan Khosravi, Atefeh Abedini, et al.
Clinical Therapeutics|April 27, 2020
Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical TrialHamid Rezvani, Seyed Mohammadreza Mortazavizadeh, Abolghasem Allahyari, et al.
BMC Cancer|September 7, 2022
Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trialAbolghasem Allahyari, Ali Ehsanpour, Behrouz Najafi, et al.
Pageof 5